Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 July 2024
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
The Extraperitoneal approach to left sided colorectal resections ( EXPERTS) ProcedureStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
AI-supported colorectal polyp detectionStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC